Merck & Co., Inc. vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while Consumer Discretionary Select Sector SPDR Fund trades at $112.85 (market cap $21.89B). The key difference: Merck & Co., Inc. is far larger — about 16× Consumer Discretionary Select Sector SPDR Fund's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Consumer Discretionary Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Consumer Discretionary Select Sector SPDR Fund for 114 Days on average.
| MRK | XLY | |
|---|---|---|
Market Cap | $351.28B | $21.89B |
Volume | 7,969,665 | 5,690,342 |
Sector | Health | — |
52-Week High | $156.43 | $124.52 |
52-Week Low | $82.49 | $105.64 |
Typical Hold Time | 98 Days | 114 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01 billion in 2025, and net income reached $18.25 billion. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, with institutional investors increasing stakes.
The outlook for Merck is supported by analyst consensus with a $158.78 price target and 68% buy ratings, but risks include high valuation multiples like a P/E of 113.9 and competitive pressures in the pharma sector. The stock's investment appeal hinges on pipeline execution and integration of acquisitions amid a challenging technical backdrop.
XLY trades at $111.70 with a modest 0.31% daily gain, showing stability amid mixed technical signals. The ETF maintains a bullish overall technical rating despite underperforming consumer staples peers year-to-date. Analyst consensus remains unanimously positive with 100% buy ratings, though recent news highlights concerns about persistent underperformance versus the S&P 500 and inflationary pressures on consumer discretionary spending.
The outlook for XLY hinges on consumer resilience amid inflation, with potential catalysts from holiday sales growth and 'funflation' trends. Key risks include continued market underperformance and sensitivity to economic cycles. Institutional sentiment appears cautiously optimistic given the concentrated buy ratings, though technical indicators suggest near-term consolidation around current price levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →